GILOTRIF

Gilotrif has been proven to be an effective treatment for the specific type of lung cancer mentioned earlier. This medication has the ability to extend the duration of time during which your cancer does not progress.

For patients who were given the recommended initial dosage of 40 mg/day of afatinib, the median overall survival (OS) was 45.3 months (with a 90% confidence interval of 37.6-47.6), the 2-year OS rate was 82%, and the median time to treatment failure (TTF) was 28.1 months.

Inform your doctor immediately if you experience any severe side effects, such as changes in vision, eye pain or redness, sensitivity to light, or eye discharge indicating eye disease. Also, report any symptoms of low potassium levels in the blood, such as muscle cramps, weakness, or irregular heartbeat, as well as signs of a bladder infection, such as burning sensation.

The US FDA has approved oral afatinib (Gilotrif) for the initial treatment of metastatic non-small-cell lung cancer (NSCLC) patients who have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations. This approval is contingent upon the use of a US FDA-approved test to detect these mutations.

The interim results from a real-world study show that patients with non-small cell lung cancer (NSCLC) and EGFR deletion 19 (del19) positive tumors, who were treated with sequential afatinib (Gilotrif) followed by osimertinib (Tagrisso), had a long-term overall survival (OS) of nearly 4 years. This treatment approach also proved effective for patients with acquired T790M mutations.

Gilotrif (afatinib) is a medication prescribed for the treatment of non-small-cell lung cancer (NSCLC) resulting from abnormal epidermal growth factor receptor (EGFR) gene mutations.

Follow your doctor’s instructions and take this medication orally, typically once a day. Make sure to take it at least 1 hour before or 2 hours after eating. The prescribed dosage will depend on your medical condition, how you respond to the treatment, and any other medications you are currently taking.

Information on Gilotrif Prices, Coupons, and Patient Assistance Programs. Gilotrif (afatinib) is a medication in the multikinase inhibitors drug class and is often prescribed for Non-Small Cell Lung Cancer. The price for a 30-tablet supply of Gilotrif oral tablets in 20 mg strength is approximately $11,713, but this cost may vary depending on the pharmacy.

The occurrence of alopecia related to these drugs varies depending on the drug: afatinib has a rate of 11.9% and cetuximab and erlotinib have a rate of 8.9%. Additionally, EGFR inhibitors can rarely cause the development of inflammatory alopecia.

The objective response rates were similar in both the 40 mg/day group (72.2%) and the <40 mg/day group (71.6%). Additionally, there was no significant difference in the proportions of patients with stable disease and progressive disease between the two treatment groups after receiving afatinib treatment.

After studying over 3800 patients, including 1638 NSCLC patients treated with 50 mg and 497 NSCLC patients with 40 mg/d monotherapy, the safety profile showed common side effects such as diarrhea (96%), rash/acne (90%), stomatitis (73%), nail abnormalities (62%), nausea (25%), ocular toxicity (23%), and emesis (22%).

Additionally, inform your doctor if you use contact lenses. If you experience difficulty breathing, coughing, rapid or irregular heartbeat, sudden weight gain, swelling in your ankles or legs, or unusual fatigue or weakness, consult your doctor immediately. Before using this medication, discuss with your doctor if you are planning to have children.

In the first-line setting, the median progression-free survival (PFS) was 17.8 months (95% CI: 13.7-21.5 months), while the overall survival (OS) was 39.5 months (95% CI: 34.4- not reached). Additionally, the response rate (RR) was 64.4%.

Gilotrif (afatinib) is a medication prescribed for the treatment of non-small-cell lung cancer (NSCLC) caused by an abnormal EGFR gene or genes. It is classified as a small molecule drug and functions as an EGFR tyrosine kinase inhibitor.

Afatinib is approved for treating patients with metastatic squamous NSCLC who have progressed after platinum-based chemotherapy. This indication is based on the promising efficacy observed in the clinical trial LUX-Lung 8 [NCT01523587]. Previous studies have shown that patients with metastatic squamous NSCLC who receive afatinib experience a significantly longer overall survival.

According to a study by Topalian et al. (CA209-003), patients with pretreated NSCLC who received two years of nivolumab treatment experienced a long-term benefit, with an estimated 5-year survival rate of 16%.

Afatinib is a type of tyrosine kinase inhibitor (TKI) that forms a permanent bond with the intracellular tyrosine kinase domain of EGFR, ErB2/Her2, and ErB4/Her4.

The overall response rate (ORR) of patients who received afatinib was 75.7%. Among patients with initial brain metastasis who did not receive local treatment, the rate of central nervous system (CNS) response was 67.0%. The CNS progression-free survival was 24.70 months (95% CI: 19.84-33.15 months).

The median survival after a follow-up of 8 months was found to be 4.9 months (95% CI 3.3-5.7), with a 1-year survival rate of 29% (95% CI 17-40%).

As long as the treatment remains effective and the side effects are manageable, it is typical to continue taking afatinib.

Dosing: The dosage of this medication will vary for each individual patient. It is important to follow the prescribed dose as directed by your healthcare provider.

Missed Dose: In the event that you forget to take a dose of this medication, take it as soon as you remember. However, if it is close to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule.

Storage: Proper storage of this medicine is crucial to maintain its effectiveness. Store it in a cool, dry place away from direct sunlight and moisture. Keep it out of reach of children and pets. Follow any specific storage instructions provided by your healthcare provider or on the medication packaging.

Afatinib is a type of targeted therapy that effectively blocks the activity of the ErbB family of tyrosine kinases in a permanent manner.

This medication is classified as a kinase inhibitor and functions by inhibiting the growth of cancer cells. It targets the epidermal growth factor receptor (EGFR) protein in certain tumors.

Afatinib, an irreversible inhibitor of both wild-type and mutant EGFR, competes with EGFR at their ATP binding region and interacts with C773 and C797 residues (Nelson et al., 2013). EGFR mutations in NSCLC are associated with increased malignancy and metastasis.

Company: Boehringer Ingelheim Pharmaceuticals, Inc. is a pharmaceutical company.

Afatinib, a kinase inhibitor, is a generic drug that works by inhibiting the growth of cancer cells.

GILOTRIF is approved for use as the initial treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations, as determined by an FDA-approved test. More information can be found in the Clinical Pharmacology (12.1) and Clinical Studies (14.1) sections.

GILOTRIF is a prescribed medication for individuals with non-small cell lung cancer (NSCLC) who have specific abnormal epidermal growth factor receptor (EGFR) genes that are not resistant. Your healthcare provider will conduct a test to determine if GILOTRIF is suitable for you.

Afatinib, sold under the brand name Gilotrif, is exclusively available in tablet form for oral consumption. It is prescribed for the treatment of metastatic non-small cell lung cancer (NSCLC).

On January 12, 2018, the FDA approved afatinib (Gilotrif, Boehringer Ingelheim Pharmaceutical, Inc.) for the treatment of previously untreated, metastatic non-small cell lung cancer (NSCLC) with non-resistant EGFR mutations.

Belonging to a group of drugs known as kinase inhibitors, Afatinib is a medication.

Afatinib, a cancer treatment being developed by Boehringer Ingelheim, is an irreversible inhibitor of the ErbB family of tyrosine kinases. It is administered orally once daily.